mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients
Open Access
- 12 January 2023
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 3137-3142
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K24AI144954)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK120518, T32DK007713)
This publication has 13 references indexed in Scilit:
- Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipientsAmerican Journal of Transplantation, 2022
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2021
- Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesTransplantation, 2021
- Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking BelataceptTransplantation, 2021
- Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipientsAmerican Journal of Transplantation, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virusAmerican Journal of Transplantation, 2021
- OPTN/SRTR 2018 Annual Data Report: KidneyAmerican Journal of Transplantation, 2020
- Effective communication of standard errors and confidence intervalsBiostatistics, 2008